Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 524.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Jim Banks (R-IN)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Bill to improve drug safety and prevent counterfeit medications from reaching patients.
The problem
Counterfeit and unsafe drugs circulate in markets, putting public health at risk. People need assurance that medicines are genuine and safe.
The proposal
Establishes standards and tracking systems for pharmaceutical supply chains. Creates tools to identify fake drugs before they reach patients.
The impact
Patients, pharmacies, drug manufacturers, and healthcare providers gain safer drug distribution systems and better ways to spot counterfeit medications.
People gain trust in the medicines they take. Knowing drugs are verified as genuine makes patients more confident in their treatments and medications.
Better tracking systems help identify and prosecute criminals selling fake drugs. This supports security efforts against drug trafficking networks.
Counterfeit drugs cause serious harm or death. Better tracking and identification systems help keep dangerous fake medicines away from patients. This protects public health.
Preventing adverse drug events from counterfeit medications reduces emergency room visits and hospitalizations. This lowers overall healthcare spending for patients and systems.
Establishing tracking systems and new safety measures requires significant funding. Drug manufacturers and pharmacies face costs to comply with new standards and technology.
New verification procedures could slow drug distribution to patients. Pharmacies may experience delays filling prescriptions during implementation of tracking systems.
Small independent pharmacies may struggle with compliance costs and technology requirements. Larger chains can better afford new systems, creating unfair competition.
Drug tracking systems collect personal medication data. Privacy advocates worry about how this sensitive health information is stored and protected.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.